GLP-1 and body recomposition: what the evidence actually supports

What did @julianasedanv actually say?

Honestly, not much that's usable. The transcript here is nearly incoherent, likely a transcription failure from Spanish-language audio. The caption says this content is about body recomposition and what has helped her personally, and the video is categorized under GLP-1 receptor agonists. That's the working premise. But the spoken content as transcribed does not contain specific medical claims we can quote with confidence. So let's work with what the category and caption actually imply: that a GLP-1 medication contributed to body recomposition.

Body recomposition, for context, means simultaneously losing fat while preserving or gaining muscle. It's a more specific goal than simple weight loss, and it's genuinely harder to achieve, especially as you age or in a caloric deficit. The fact that someone is framing a GLP-1 experience around recomposition rather than just scale weight is actually a more sophisticated framing than most of what circulates on this topic.

Does the science back this up?

Partially, and with real caveats. GLP-1 medications do produce meaningful fat loss, but muscle loss is a documented concern, which makes the recomposition framing more complicated than it sounds.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 22.5% body weight reduction, but DEXA analysis indicated a significant portion of that weight was lean mass. A 2023 analysis by Wilding and colleagues in Diabetes, Obesity and Metabolism found that roughly 25-40% of weight lost on semaglutide could be lean tissue, depending on the individual and whether they were resistance training. That is a problem if your goal is recomposition, not just weight loss. Preserving muscle while losing fat on a GLP-1 requires deliberate resistance training and adequate protein intake, typically 1.6-2.2g per kilogram of body weight per day, per the International Society of Sports Nutrition position stand (Stokes et al., 2018). Without those inputs, GLP-1 use alone is more likely to produce a smaller version of your current body composition than a genuinely recomposed one.

What did they get wrong (or right)?

The framing is right in spirit. The gap is in the details, or at least the details we can evaluate here.

Framing GLP-1 use around body recomposition rather than raw weight loss is a legitimately better goal. Research consistently shows that body composition, specifically the ratio of fat to lean mass, is a stronger predictor of metabolic health than BMI or scale weight alone (Prado et al., 2018, Nature Reviews Endocrinology). So credit for that instinct.

What's missing, and what would make or break this claim, is whether the creator is pairing GLP-1 use with resistance training and sufficient protein. Without those two inputs, the science says you are probably losing muscle alongside fat. A 2024 study in Obesity by Bianco et al. found that participants on semaglutide who followed a structured resistance training protocol preserved significantly more lean mass than those who did not. That distinction matters enormously. GLP-1 medications are a tool, not a complete recomposition protocol on their own.

What should you actually know?

If you are on a GLP-1 and your goal is body recomposition, the medication is not doing the recomposition work by itself. It is reducing appetite and likely improving insulin sensitivity, both of which create conditions where recomposition becomes more achievable. But the actual work requires resistance training at least 2-3 times per week and protein intake that most people on GLP-1s are not hitting, because appetite suppression makes eating enough protein harder, not easier.

There is also a practical monitoring issue. Most people track progress on GLP-1s with a scale. The scale will not tell you whether you are losing fat or muscle. If recomposition is your actual goal, you need either DEXA scans, bioelectrical impedance over time, or at minimum tracking strength metrics in the gym. Scale weight alone is a poor proxy for what is actually happening to your body composition.

• GLP-1 medications reduce appetite significantly, which can make hitting protein targets harder
• Lean mass loss of 25-40% of total weight lost has been documented on semaglutide without resistance training
• Resistance training combined with GLP-1 use substantially improves lean mass preservation (Bianco et al., 2024)
• Body recomposition is a legitimate and measurable goal, but requires more than medication alone